Tirzepatide (Zepbound) is the first drug approved by the FDA for obstructive sleep apnea (OSA) in adults with obesity. The SURMOUNT-OSA trial shows up to 63% reduction in apnea-hypopnea index.
ReadOn January 13, 2026, the FDA officially confirmed that GLP-1 drugs like semaglutide and tirzepatide do not increase suicide risk. The suicide warning is being removed from drug labels.
ReadThree new scam vendors have been verified on the Vendor Radar, while the FDA warns of counterfeit Ozempic (semaglutide) in the supply chain and launches Import Alert 66-80 against illegal GLP-1 imports. An overview of current risks for peptide buyers.
ReadThe FDA sent a third wave of 25 warning letters to telehealth companies in mid-June 2026 for misleading claims about compounded GLP-1 drugs. The agency warns patients about unapproved copycat products.
ReadA new Chainalysis report reveals the gray-market peptide crypto ecosystem has surpassed $100 million annually, with former fentanyl precursor suppliers entering the space and independent safety testing collapsing.
ReadA prespecified analysis of the SELECT trial (The Lancet, October 2025) reveals that semaglutide reduces major adverse cardiovascular events by 20% - and this benefit is largely independent of baseline weight or amount of weight lost.
ReadThe FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, effectively ending large-scale compounding of these GLP-1 drugs. New safety data reveals dangerous impurities including formaldehyde adducts in compounded products.
ReadUS poison control centers report a 1,500 % increase in GLP-1-related calls since 2019, driven by dosing errors with compounded semaglutide and tirzepatide. The FDA has received over 1,150 adverse event reports, including hospitalizations and deaths.
ReadEli Lilly's triple agonist retatrutide achieved up to 28.3 % weight loss in the Phase 3 TRIUMPH trials - the highest ever recorded in a Phase 3 GLP-1-class study. The 2025/2026 results also show significant improvements in osteoarthritis pain, liver fat, and prediabetes reversal.
Read
